Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 158 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer August 28, 2020 EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... October 6, 2023 Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like... January 5, 2021 FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR... May 28, 2021 Load more HOT NEWS Can Using Hair Dyes or Hair Relaxers Impact Your Cancer Risk? ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in... From Awareness to Action: Putting Cancer Disparities in the Rearview Mirror
